What the Evidence Says About Haploidentical Stem Cell Transplantation in China: The Beijing Protocol Explained for International Patients
A plain-language guide to the clinical evidence behind China's most widely used approach to half-matched donor transplantation — for patients with leukaemia, aplastic anaemia, and related blood disorders.
Quick Answer
The Beijing Protocol is a clinically validated approach to haploidentical stem cell transplantation — using a half-matched family donor — developed at Peking University and documented in peer-reviewed journals including Blood, Haematologica, and Journal of Clinical Oncology. For international patients with leukaemia, aplastic anaemia, or related blood cancers, it represents an established treatment pathway in China that has demonstrated outcomes comparable to fully matched donor transplants across multiple prospective multicentre studies.
Primary
Source
Peer-Reviewed Review Article · Haematologica, March 2025
Optimization of T-cell-replete haploidentical hematopoietic stem cell transplantation: the Chinese experience
Mo X, Pei X, Huang X · Peking University People's Hospital & Peking University Institute of Hematology · Haematologica 2025;110(3):562–575
View full article at Haematologica.org →When a diagnosis involves leukaemia, aplastic anaemia, lymphoma, or another serious blood disorder, the questions come fast: Is there a donor for me? Am I too old for a transplant? What if I relapse? For many patients, the answers they receive locally leave significant room for doubt. For international patients and caregivers, seeking cancer treatment in China has become an increasingly data-driven decision — not driven by hope alone, but by published clinical evidence from peer-reviewed journals. The Beijing Protocol is at the centre of that conversation.
The fundamental challenge in bone marrow transplantation — known clinically as haematopoietic stem cell transplantation (HSCT) — has always been donor availability. Fewer than 30% of patients have a fully HLA-matched sibling. For those without one, the search turns to unrelated donor registries, which can take months and still fail. Haploidentical transplantation uses a half-matched family member such as a parent, child, or sibling — nearly every patient has a haploidentical relative. The obstacle has been immune rejection and graft-versus-host disease (GvHD). Before 2000, outcomes from haploidentical transplants were poor enough that the approach was rarely recommended. The Beijing Protocol changed that calculus.
What Is the Beijing Protocol? A Plain-Language Overview
The Beijing Protocol was developed by Professor Xiaojun Huang and colleagues at the Peking University Institute of Hematology. Its core innovation was finding a way to make the immune system tolerate a half-matched graft without stripping out the donor's T-cells — which are essential for fighting both infection and residual cancer cells.
The approach uses two medications — granulocyte colony-stimulating factor (G-CSF) and anti-thymocyte globulin (ATG) — in a carefully timed conditioning sequence before transplant. This primes both the patient's and donor's immune systems to coexist, reducing the risk of violent rejection while preserving the graft's cancer-fighting ability. Traditional methods tried to make the graft "safer" by removing the immune cells that cause GvHD. The Beijing Protocol instead teaches the two immune systems to negotiate — retaining the graft's power against the cancer while significantly reducing the risk of severe immune complications.
Key clinical achievements documented in peer-reviewed research
Outcomes comparable to fully matched sibling transplants
Multiple prospective multicentre studies have shown that patients receiving haploidentical HSCT under the Beijing Protocol achieve survival and relapse rates statistically similar to fully matched sibling transplants — a benchmark considered unreachable a generation ago.
Stronger anti-cancer effect in high-risk cases
For patients with high-risk leukaemia subtypes, haploidentical transplantation using this approach has shown evidence of a stronger graft-versus-leukaemia effect compared to matched sibling transplants — the immune response may be more aggressive toward residual cancer cells, potentially reducing relapse risk.
Expanded eligibility to older patients
Traditional intensive conditioning was too toxic for patients over 55. Modified protocols for patients aged 55–65 have been developed and published, with a prospective Phase II study demonstrating haploidentical HSCT achieving a relapse rate of approximately 17% versus 75% in the chemotherapy comparison group among intermediate- and high-risk AML patients in this age range.
Application beyond blood cancers
The protocol has been extended to severe aplastic anaemia, thalassaemia, Fanconi anaemia, and inherited metabolic diseases. In aplastic anaemia, failure-free survival rates for haploidentical transplants are now comparable to fully matched sibling transplants — data published in British Journal of Haematology and Haematologica.
The Evidence Base: Published in International Peer-Reviewed Journals
For international patients weighing a major medical decision, the credibility of the evidence matters as much as the clinical outcomes themselves. The Beijing Protocol is documented in journals that apply rigorous peer review, including Haematologica, Blood, Journal of Clinical Oncology, Leukemia, and British Journal of Haematology.
A 2025 review article published in Haematologica — one of Europe's most respected haematology journals — summarises the current state of optimisation across every major dimension of haploidentical HSCT: graft function, GvHD prevention, relapse prophylaxis, and integration with novel immunotherapies. The article reflects data from prospective multicentre trials, randomised controlled studies, and national registry analyses.
Key data points from the published evidence
- The Beijing Protocol now accounts for over 90% of haploidentical HSCT performed in China
- Haploidentical transplants grew from 29.6% of all allogeneic HSCT in China in 2008 to 63% by 2019 — representing nearly 8,000 procedures in a single year
- Chinese centres have published randomised controlled trial data on GvHD prophylaxis optimisation, including reduced-dose combinations that decreased GvHD incidence while improving survival
This level of evidence — prospective, multicentre, published internationally — is what distinguishes the Beijing Protocol from experimental or centre-specific claims. If you are evaluating treatment options and would like a specialist review of your records before making any decisions, an online MDT consultation can help clarify whether haploidentical transplantation is appropriate for your situation and what the current evidence suggests for your specific diagnosis.
What International Patients Should Expect When Considering Treatment in China
The scale of China's HSCT programme has direct implications for international patients — in ways that matter clinically, not just administratively.
Volume and experience
Centres performing thousands of transplants per year accumulate institutional knowledge that affects outcomes at every stage: conditioning protocol calibration, early complication detection, post-transplant monitoring, and salvage strategies when complications arise. The Peking University Institute of Hematology is among the most experienced haploidentical transplant programmes in the world by case volume.
Innovation in complication management
Beyond the core transplant protocol, Chinese researchers have developed and published validated approaches to complications that remain challenging globally:
- An AI-based predictive model for post-transplant relapse risk in AML, enabling more individualised intervention planning
- Randomised controlled trial evidence supporting N-acetyl-L-cysteine prophylaxis to reduce poor graft function in high-risk patients
- Donor-derived NK cell infusion after transplant, demonstrated in a Phase II randomised trial to reduce disease progression in high-risk myeloid malignancy patients
- CMV-specific cytotoxic T-cell therapy achieving complete response rates of approximately 90% at six weeks for a viral complication that remains a significant cause of transplant failure globally
- Umbilical cord mesenchymal stem cell infusion to reduce chronic GvHD, supported by multicentre randomised controlled trial data
Integration of CAR-T therapy and transplant
For patients with relapsed or refractory B-cell ALL — one of the most difficult situations in haematology — Chinese centres have published outcomes data on combining CAR-T cell therapy as a bridge to haploidentical HSCT. Two-year event-free survival rates of 76% and overall survival of 84.3% have been reported in this population — which historically faces very poor prognosis. This represents one of the most clinically significant areas of integration between novel cell therapies and transplant in current haematology practice.
Language and coordination for international patients
International patients typically work through medical coordination services that facilitate medical record translation, pre-consultation preparation, logistics, and communication during treatment. Understanding what this process involves before committing to any decision is important — our resources section provides guidance on how international patients navigate this pathway.
The Role of Caregivers in the Treatment Journey
A bone marrow transplant is not a brief procedure. From initial evaluation and conditioning through engraftment, monitoring, and the early post-transplant period, the process typically spans several months. For international patients travelling to China, this means caregivers — family members or close support persons — are not peripheral to the experience. They are central to it.
Caregivers accompanying patients should expect to be involved in daily monitoring during the inpatient phase, communication with the medical team (often through an interpreter or coordinator), and decision-making support if complications arise. Understanding the arc of the treatment — what the first weeks look like, when the critical risk windows are, what "engraftment" means and why it matters — helps caregivers feel less reactive and more prepared.
Emotionally, the period of waiting for engraftment confirmation — typically around day 28 post-transplant — is often described by families as one of the most difficult. Medical teams at experienced centres are accustomed to supporting international families through this uncertainty.
For caregivers of patients still in the decision phase, a structured second opinion process is often valuable before committing to a treatment plan. A multidisciplinary team (MDT) review of the patient's records can clarify staging, donor compatibility considerations, conditioning intensity options, and realistic outcome expectations in the context of the patient's specific disease profile.
After Treatment: What Comes Next
Discharge from the transplant centre does not mean the treatment is complete. The post-transplant period — particularly the first 100 days — involves ongoing monitoring for GvHD, infection, and graft function. For international patients returning home after treatment in China, continuity of care requires coordination between the Chinese treating centre and local physicians.
Follow-up monitoring schedule
Chinese centres typically provide a structured follow-up protocol, including measurable residual disease (MRD) testing at specified intervals — a sensitive method for detecting very early signs of relapse before symptoms develop. Understanding this schedule and ensuring it can be implemented locally is an important part of discharge planning.
GvHD surveillance
Chronic GvHD can develop weeks or months after transplant and may affect the skin, liver, lungs, joints, or eyes. Patients and caregivers should know the warning signs and have a local physician familiar with post-transplant care who can evaluate and manage any emerging symptoms.
Pre-emptive intervention access
If MRD monitoring indicates early relapse signals, Chinese centres now offer a range of pre-emptive strategies — donor lymphocyte infusion, interferon-alpha therapy, or donor-derived CAR-T cell therapy — that can be initiated before clinical relapse develops. For patients whose situation involves treatment after lymphoma relapse, these post-transplant strategies are especially relevant to understand in advance.
Emotional recovery
Patients who have undergone HSCT often describe the first year post-transplant as emotionally complex — relief, fatigue, uncertainty, and adjustment all coexist. Connecting with patient communities and, where available, psychological support tailored to transplant survivors, can be meaningful during this phase.
If you are at the decision stage — evaluating whether haploidentical transplantation is appropriate, which conditioning approach may apply, or how to prepare for travel — a structured MDT consultation allows your records to be reviewed by a specialist team before any commitment is made. This is typically the most constructive first step for international patients navigating a complex haematology decision.
Considering Blood Cancer Treatment Options in China?
For international patients evaluating haploidentical transplantation or other advanced blood cancer therapies, the first step is usually a structured review of your existing records. An MDT consultation allows a specialist team to assess your situation — before any travel commitment is made.
Explore MDT ConsultationFrequently Asked Questions
How is the Beijing Protocol different from haploidentical transplant approaches in Europe or the United States?
The Beijing Protocol uses G-CSF and ATG-based conditioning rather than post-transplant cyclophosphamide, which is more common in Western centres. Both protocols are internationally recognised and studies show broadly comparable outcomes. The Beijing Protocol has the largest published clinical experience globally, almost entirely generated at Chinese centres. The choice between protocols depends on individual patient factors and institutional expertise.
Is haploidentical transplantation suitable for older patients?
Traditional intensive conditioning was not well tolerated by patients over 55–60. Chinese centres have developed and published modified conditioning regimens for patients aged 55–65, with Phase II trial data supporting use in this age group. Eligibility depends on overall health status, comorbidities, and disease characteristics — an individualised evaluation by a specialist team is necessary.
What blood cancer diagnoses can be treated with the Beijing Protocol?
The protocol was initially developed for leukaemia (AML and ALL) but has been extended to myelodysplastic syndrome, severe aplastic anaemia, Hodgkin lymphoma in relapsed or refractory cases, thalassaemia, sickle cell disease, Fanconi anaemia, and certain inherited metabolic storage diseases. Outcomes data exists for all of these indications in the published literature.
How do I know if a family member can be a haploidentical donor?
HLA testing of potential family members — including parents, children, and siblings — is required. Because haploidentical transplantation requires only a 50% genetic match, the majority of patients have at least one eligible family member. The treating centre's transplant team evaluates which family donor represents the most favourable option based on additional compatibility factors.
What is the process for an international patient to begin evaluation for transplant in China?
The typical pathway begins with a remote review of existing medical records — including diagnosis, staging, treatment history, and molecular testing results — by a specialist team. This can be arranged before any travel commitment is made. A structured MDT consultation provides a specialist review and recommendations, allowing patients and families to make an informed decision about whether to proceed.
Medical disclaimer: ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice. All treatment decisions — including decisions about stem cell transplantation, conditioning protocols, and donor selection — should be made in consultation with a qualified haematologist or oncologist. Individual eligibility varies significantly and must be assessed by a specialist team.
Related Guides
CAR-T Therapy for Lymphoma: Who Is Eligible and What to Expect
Eligibility criteria, the step-by-step CAR-T process, and what international patients should prepare before considering CAR-T in China.
DLBCL Treatment Options: What Should You Do Next?
Diffuse large B-cell lymphoma treatment explained — from first-line chemoimmunotherapy to CAR-T for relapsed or refractory disease in China.
Lymphoma Treatment After Relapse: What Options Exist
A clear guide to treatment options after lymphoma relapse — from salvage therapy and stem cell transplant to CAR-T and MDT review.
Exploring Blood Cancer Treatment Options in China?
Our coordination team can explain the process for arranging a specialist evaluation, support medical record preparation, and help you understand what a structured MDT review involves — before any travel decision is made.